Networks Board and Taskforce

Each ECNP Network is led by a chair and a co-chair*. Chairs and co-chairs of Networks and thematic working groups (TWGs) form the Networks Taskforce, which reports to the Networks Board and meets twice a year. The Networks Board guides the ECNP Networks.* Thematic working groups have only the chair.

Networks board

Gitte-Knudsen-2Chair: Gitte Moos Knudsen, Denmark
Prof. Gitte Moos Knudsen is President-elect of ECNP and professor at Dept. Neurology, Rigshospitalet and University of Copenhagen, Denmark. She is a translational neurobiologist and clinical neurologist with interest in advanced methodological developments that she subsequently applies in her research to address pertinent neurobiological and clinical issues. Her scientific interests include the neurobiology of cerebral neurotransmission and neuropharmacological interventions with particular emphasis on molecular brain imaging. Her lab investigates human brain disease mechanisms and predict brain responses to categories of neuromodulatory interventions as well as treatment efficacy. For this purpose, they use PET brain scanning to image brain receptors and receptor occupancy, and fMRI to evaluate drug effects on the brain hemodynamic response as well as the brains regional interactions, i.e., functional connectivity.
Co-chair: Nic van der Wee

Network taskforce 

ADHD across the lifespan 

Barbara FrankeChair: Barbara Franke, The Netherlands
Barbara Franke is full Professor of Molecular Psychiatry based at the Human Genetics and Psychiatry departments of the Radboud University Medical Center (Radboudumc, Radboud University, Nijmegen). She is also Principal Investigator at the Donders Institute for Brain, Cognition and Behaviour. At Radboudumc, she chairs the Division of Genome Research and the Radboud Research Theme Neurodevelopmental Disorders. She is an elected member of the Royal Netherlands Academy of Arts and Sciences (KNAW), the Royal Holland Society of Sciences and Humanities (KHMW), and of Academia Europaea. Her research is focused on understanding the genetic contribution to neurodevelopmental psychiatric disorders, especially ADHD and its comorbidities. Beyond gene-finding, her group uses complementary approaches (bioinformatics, iPSC-derived neurons, small animal models, neuroimaging genetics) to map biological pathways from gene to disease. She has obtained prestigious grants, including a prestigious personal Vici grant from the Netherlands Organisation for Scientific Research (NWO) and several EU consortium grants. She coordinates the EU-FP7 Aggressotype consortium on aggression and the EU-H2020 European Training Network MiND on autism-comorbidity in ADHD; she also leads work packages in the EU-funded consortia CoCA and Eat2beNICE and is a member of the IMI2 consortium PRISM. She founded and coordinates the International Multicentre persistent ADHD Collaboration (IMpACT) and the ECNP Network ‘ADHD across the Lifespan’, is a co-founder of the neuroimaging genetics consortium ENIGMA, and leads ENIGMA’s ADHD Working Group and the Psychiatric Genomics Consortium’s ADHD Working Group. In 2018, she was elected to become a member of the Board of Directors of the International Society of Psychiatric Genetics (ISPG).

Co-chair: Andreas Reif, Germany
Prof. Andreas Reif is Chair of the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy of the University Hospital Frankfurt. His clinical and research interest encompass mood disorders, especially treatment-resistant depression, suicidality and bipolar disorder, as well as adult ADHD. For these entities, he set up specialized clinical programs along with corresponding research groups utilizing a broad range of methods from genetics, molecular biology, animal behavior up to human experimental medicine and neuroimaging following the mission of translational research in psychiatry. The ultimate goal is to provide means – be it biomarkers or disease subtypes – to provide the optimal treatment for the right patient at the right time. He is involved in highly productive research networks such as IMpACT, ConLiGen, CoCA, ENIGMA, the PGC and BipoLife underscoring his firm believe in collaborative science and the European idea.   


Anxiety Disorders (ADRN)

Borwin BandelowChair: Borwin Bandelow, Germany
Prof. Dr. Borwin Bandelow has retired from his work as a professor of Psychiatry and Psychotherapy at the Department of Psychiatry and Psychotherapy, University Medical Centre of Göttingen. He is still working in the same department as a Senior Scientist. Prof. Bandelow is specialized in anxiety disorders. His recent work was on the neurobiology of anxiety disorders and on the efficacy of medication and psychotherapy for these disorders.

Katharina DomschkeCo-chair: Katharina Domschke, Germany
Katharina Domschke, MA, MD, PhD, is Full Professor of Psychiatry and Chair of the Department of Psychiatry and Psychotherapy, University of Freiburg, Germany. Her clinical and teaching focus is on anxiety disorders, depression, OCD and PTSD. Scientifically, Prof. Domschke is a renowned expert in genetics, epigenetics, imaging genetics and pharmacogenetics of anxiety, anxiety disorders and depression.




Bipolar Disorders (ENBREC)

Ole AndreassenChair: Ole Andreassen, Norway
Ole Andreassen is Professor in psychiatry at the University of Oslo, Division of Mental Health and Addiction, and attending psychiatrist, Oslo University Hospital, Oslo, Norway. He did his PhD in psychopharmacology at University of Bergen and his post doc training in neuroscience at Massachusetts General Hospital-Harvard Medical School where he investigated mechanisms of neurodegeneration. He did his psychiatry residency at Oslo University Hospital, and is now the Director of Norwegian Centre for Mental Disease Research (NORMENT), a KG Jebsen Centre, one of the largest mental health research groups in Scandinavia. The centre has a translational research approach and apply clinical and neurocognitive, brain imaging phenotypes and molecular genetics tools to identify causes and underlying pathophysiology of severe mental disorders, focusing on bipolar disorder. Prof. Andreassen build his research on the Nordic advantages, such as public health care system, large biobanks, health registries and homogenous population, and has recently developed a biostatistical program to improve analysis of the ever constantly increasing research data.

Michael BauerCo-chair: Michael Bauer, Germany
Michael Bauer, MD, PhD, is Professor of Psychiatry and Chair of the Department of Psychiatry and Psychotherapy at the University Hospital Carl Gustav Carus, Technische Universität Dresden, in Germany, where he is also Physician-in-Chief at the Psychiatric Hospital and Outpatient Clinics. For his research in the field of mood disorders, he received several international and national awards/prices, e.g., the NARSAD Independent Investigator Award, the ARETÄUS Price for “Exceptional dedication in the field of bipolar disorder” by the German Society for Bipolar Disorders, the AGNP-Prize for Research in Psychopharmacology, Achievements in the Field of Treatment of Mood Disorders with Thyroid Hormones, and the Anna Monika Prize for research in neurobiology and treatment of depressive disorders (2017). He is President of the International Group for the Study of Lithium-Treated Patients (IGSLi) and chairs the World Federation of Societies of Biological Psychiatry’s Task Force on Treatment Guidelines for Unipolar Depressive Disorders. Dr. Bauer is Editor-in-Chief of the International Journal of Bipolar Disorders, and of Pharmacopsychiatry, and has (co-)authored more than 400 articles published in peer-reviewed journals or books in the field of mood disorders.     

LarVedel-Kessing-1Co-chair: Lars Vedel Kessing, Denmark   
Dr. Kessing, MD, DMSc, has since 2002 been appointed as Professor in psychiatry at the Psychiatric Center Copenhagen, Rigshospitalet, and the University of Copenhagen, Faculty of Health and Medical Sciences. Dr. Kessings scientific contributions are within clinical, epidemiological including register-based, genetic and neurobiological research in bipolar and unipolar affective disorders. Dr. Kessing is the author of more than several peer reviewed scientific papers on affective disorders and he has received a number of scientific prizes, including the US National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) Bipolar Mood Disorder Prize for “Outstanding Achievement in Bipolar Mood Disorder Research” and the Travelling Professor Award for the Royal Australian and New Zealand College of Psychiatrists. 

Child & Adolescent Neuropsychopharmacology

Alessandro Zuddas

Chair: Alessandro Zuddas, Italy 
Alessandro Zuddas is Professor of Child Neuropsychiatry at the University of Cagliari, Department of Biomedical Sciences, coordinator of the Residency in Child Neuropsychiatry, Director of the Child and Adolescent Neuropsychiatry Unit at the Pediatric Hospital (AO) "G.Brotzu" in Cagliari and head of the Center for Pharmacological Therapy in Child and Adolescent Neuropsychiatry. He was a guest researcher at the National Institute of Neurological and Communicative Disorders and Strokes, NINCDS-NIH and the National Institute of Mental Health (Child Psychiatry Branch,), NIMH-NIH, Bethesda MD, U.S. and the Hospital for Sick Children (Dept of Psychiatry), Toronto, Canada. Prof. Zuddas coordinates numerous national and international clinical research projects in psychopathology and psychopharmacology of the developmental age, including specific sections of four European projects of the 7th Framework Program (PERS, ADDUCE, STOP and MATRICS). He was Co-Editor of European Child & Adolescent Psychiatry (2005-15). He is a member of international scientific societies; coordinates the Child & Adolescent Psychopharmacology Network within the pediatric network of the European Medicine Agency (EnprEMA) and the School of Neuropsychopharmacology of the Child and Adolescent of the European College of Neuropsychopharmacology (ECNP). He is the author of numerous publications on national and international books and scientific journals.

Carmen MorenoCo-chair: Carmen Moreno, Spain
Dr. Carmen Moreno (MD, PhD) is a Child and Adult Psychiatrist at the Hospital Gregorio Marañón in Madrid and Associate Professor of the Gregorio Marañón Psychiatry Department and Complutense University School of Medicine, Madrid, Spain. Dr. Moreno completed her MD and PhD degrees at Autónoma University and Complutense University in Madrid, followed by a Research Fellowship in Child and Adolescent Psychiatry at Columbia University/New York Psychiatric Institute, New York, USA. Dr. Moreno has been focusing her career on severe early-onset psychiatric disorders, mainly psychotic and affective disorders, and autism and other neurodevelopmental disorders. She is actively involved on multinational research projects exploring key biological aspects of first-episode psychotic disorders, including multimodal neuroimaging, intermediate mechanisms such as inflammation and oxidative stress, and metabolomics. Her efforts are also focused on exploring secondary effects of psychopharmacological interventions and towards development of new treatment interventions in young patients. Dr. Moreno is actively involved on the development of clinical psychopharmacology in children and adolescents. She has served as consultant for the European Medicines Agency (EMA) and is currently serving as Co-chair of the ECNP Adolescent Child and Adolescent Neuropsychopharmacology Network, and the ECAPN, integrated in the EmprEMA. She has previously served in the ECNP Membership Committee. Dr. Moreno has published several peer-reviewed original publications and book chapters and she has presented numerous scientific communications. She has participated in more than 25 research projects, including 7 with European Union funds. She has been awarded the ECNP Research Fellowship Award, and the Awards for Young Scientists and Senior Scientists of the Spanish Association of Biological Psychiatry.

Down Syndrome and Other Genetic Development Disorders (DSG2D)

Marie-Claude-Potier-1Chair: Marie-Claude Potier, France
Dr. Marie-Claude Potier (PharmD, PhD), is director of research at Centre National de la Recherche Scientifique, co-leader of the team “Alzheimer’s disease & prions diseases” at Institut du Cerveau et de la Moelle épinière (, at the Salpêtrière Hospital in Paris, one of the leading European institute in Neuroscience where research on neurodegenerative diseases including Alzheimer’s disease (AD), Down syndrome (DS) and Parkinson’s (PD), preclinical and clinical research is mainstream. She has been working on DS for the past 25 years. She started on genomics and genetics projects and is currently developing pharmacological treatments for increasing cognition in DS and studying early stages of Alzheimer’s disease in individuals with DS. She developed mouse and cellular models to study the mechanisms leading to changes in the endo-lysosomal pathway involved in amyloid pathology. She also works on translational research programs with clinicians on-site studying cohorts of patients with AD, mild cognitive impairment or asymptomatic. Beside she has developed a microfluidic platform for studying the transcriptome of single cells and producing microfluidic devices for neuronal cultures.

Mara-Dierssen-1Co-chair: Mara Dierssen, Spain
Prof. Mara Dierssen (MD, PhD), heads the Cellular and Systems Neurobiology group of the Systems Biology program at the Centre for Genomic Regulation (CRG) in Barcelona. She has been working on Down syndrome (DS) and Alzheimer’s disease for the past 25 years. The overall goal of Prof. Dierssen research is understanding how genetic perturbation leads to molecular and cellular alterations and cognitive deficits. Her research has strongly contributed to find new clinically-effective treatments for cognitive disorders, especially Down syndrome for which she also works on translational research programs with clinicians.

Experimental Medicines

Chair: David Nutt, United Kingdom

Gerry-DawsonCo-chair: Gerry Dawson, United Kingdom
Gerry Dawson has co-chaired the Network since 2013 with the aim of establishing a European wide consortium of academic centres to develop, validate and maintain state of the art human experimental medicine models to support the discovery and development of new drug treatments in psychiatry. The Network is now firmly established and in 2016 was instrumental in bringing together the successful application to the IMI that resulted in the Psychiatric Ratings using Intermediate Stratified Markers (PRISM) consortium. With Anke Post (Roche), he leads the work package of the project that is responsible for the conduct of the clinical trial that is at the heart of the consortium to study the biological underpinnings of social withdrawal in Alzheimer’s disease and schizophrenia. More recently, he worked closely with Stephane Pollentier to form the Reward Task Optimisation Consortium (RTOC). RTOC is collectively funded by five pharma companies and brings together two SMEs with four academic members of the Network to optimise a range of tasks that provide objective, quantifiable assessments of anhedonia.


Chair: Hilleke Hulshoff Pol, The Netherlands
Co-chair: Nikolaos Koutsouleris, Germany


Suzanne DicksonChair: Suzanne Dickson, Sweden
Suzanne L. Dickson is Professor of Neuroendocrinology at the Sahlgrenska Academy at the University of Gothenburg in Sweden. Within the Nutrition Network, she is promoting activities that foster new collaborations across disciplines with a view to establishing new European-wide activities related to nutrition and brain health. Her research concerns the neurobiology of food intake, with much emphasis on the role of circulating hormones in steering relevant behaviours.


Roger AdanCo-chair: Roger Adan, The Netherlands
Roger Adan is Professor of Molecular Pharmacology at the University Medical Center Utrecht at the Utrecht University in the Netherlands. His research concerns unraveling the neural circuits that underlie behaviors relevant to psychiatry with a focus on eating disorders.



Obsessive Compulsive and Related Disorders (OCRN)

Chair: José Manuel Menchón, Spain
Co-chair: Dick Veltman, The Netherlands 

Preclinical Data Forum
Anton Bespalov

Chair: Anton Bespalov, GermanyAnton Bespalov is managing partner at PAASP (Partnership for Assessment and Accreditation of Scientific Practice) and a managing director / CSO at EXCIVA in Heidelberg, Germany. He obtained his MD degree from Pavlov Medical University (St. Petersburg) and after completion of PhD studies in St. Petersburg and Utrecht held NIH-supported Fellowships at Medical College of Virginia (Richmond, VA) and Scripps Institute (La Jolla, CA). After habilitation (DMedSci) in 2000, Anton acted as a research director of Valdman Institute of Pharmacology. In 2004, Anton joined Abbott (later AbbVie) but maintained close connections to Pavlov Medical University where he is a professor at the Institute of Pharmacology and chaired the University’s Scientific Advisory Board. During his tenure at Abbott / AbbVie as head of pharmacology department, Anton and his teams have brought several compounds into preclinical and clinical development, supported licensing and due diligence decisions. Anton has established and managed research contracts and collaborations with 100+ biotech companies, CROs and academic labs around the world and founded and led several international initiatives on preclinical data quality.

Thomas StecklerCo-chair: Thomas Steckler, Belgium
Thomas Steckler is Associate Director at Janssen R&D, Bioresearch Quality & Compliance, Animal Welfare Strategy Lead. His expertise and fields of interest are drug development, psychopharmacology, quality, animal care & use, and animal models.


Silvana GalderisiChair: Silvana Galderisi, Italy
Silvana Galderisi is Full Professor of Psychiatry and Director of the Department of Mental and Physical Health and Preventive Medicine at the University of Campania “Luigi Vanvitelli”, Naples, Italy. She is President of the European Psychiatric Association and Chairperson of the ECNP Schizophrenia Network. Her main research interests include the clinical, biological and social factors influencing schizophrenia outcome, combining a wide range of aspects, including genetics, neurocognition, social cognition, neuroimaging, psychopathology and clinical psychology. She is an expert of the clinical and neurobiological characterization of the deficit syndrome of schizophrenia. She and her collaborators presently focus on the clinical, neuroimaging, neuropsychological and genetics research on negative symptoms domains, as well as neurocognitive impairment in psychiatric disorders. She is also an expert of neurocognitive rehabilitation in patients with psychoses.

Istvan BitterCo-chair: István Bitter, Hungary
István Bitter is Professor of Psychiatry at the department of Psychiatry and Psychotherapy of the Semmelweis University, Budapest, Hungary. His current research focuses on clinical psychopharmacology (schizophrenia, especially on negative symptoms), epidemiology (comorbidity and survival in schizophrenia; ADHD). He has collaborations with basic scientists (purinergic mechanisms in schizophrenia) and clinical electrophysiologists (focus on EEG in ADHD and schizophrenia).




Chair: Danuta Wasserman, Sweden
Co-chair: Vladimir Carli, Sweden

Traumatic Stress

Eric VermettenChair: Eric Vermetten, The Netherlands
Eric Vermetten is Professor of psychiatry at Leiden University and Strategic Advisor at the Military Mental Health Department of Defense in The Netherlands. He is working on several projects related to psychotrauma: longitudinal studies in military cohorts, with multilevel phenotyping; novel approaches to therapy (e.g. VR based 3MDR) as well as novel approaches to complex trauma, (e.g. MDMA assisted psychotherapy). This extends to research on use of service dogs, social ecology of veterans, prediction models of therapy for veterans, use of ketamine in PTSD, medical cannabis and augmenting performance in high stressful situations. He also works with NATO partners on a digital approach to mental readiness and teaches on topics (e.g. complex PTSD, moral injury).  

Joseph ZoharCo-chair: Joseph Zohar, Israel
Joseph Zohar is Professor of psychiatry at Tel Aviv University, Israel. He is the founder of the World Council on Anxiety as well as the Israeli Consortium on PTSD. He currently leads the chief installation of the Israeli Defense Force for the treatment of PTSD. He is a member of the Executive Committee of ECNP, of which he is also a former president, and chairman of the Expert Platform on Mental Health. He focuses on the potential of secondary prevention in PTSD. 

Prevention of mental disorders and mental health promotion (TWG)

Paolo Fusar-PoliChair: Paolo Fusar-Poli, United Kingdom/Italy
Prof. Dr. Paolo Fusar-Poli, MD, PhD, Reader in Psychiatry & Youth Mental Health at Institute of Psychiatry, Psychology and Neuroscience at King’s college of London (UK) and Associate professor of Psychiatry at the Brain and Behavioral Sciences Department, University of Pavia (Italy), has more than 10 years of experience in the prevention of psychosis, leading one of the oldest and largest clinical services of this type in Europe (OASIS). His lab is currently investigating Precision Medicine and Clinical Prediction strategies that are based on Evidence Based Medicine, in combination with experimental psychopharmacological treatments for the prevention of mental disorders, such as intranasal oxytocin, phosphodiesterase inhibitors and cannabinoids. He has long-standing expertise in managing research networks: he is coordinating the PSYSCAN and HARMONY international research networks for patients at risk of psychosis. Since 2015, he has been listed every year by Thomson Reuters as one of the 100 “most influential scientific minds” and “top 1% highly cited scientists in the area of psychiatry”.